UnknownPhase 2

Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage

390 participantsStarted 2021-03-01

Plain-language summary

pending

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent from the patient or legally acceptable representative * Males and females * Diagnose as hypertensive intracerebral hemorrhage * Onset of symptoms within 6\~48 hours * Position of bleeding major in basal ganglia * The sum of scores on items 5 and 6 on the NIHSS were \>= 2 at baseline and the total score (items 1-11) was \>=6 and \<=20 * Volume of Hematoma \<= 30 ml * Premorbid mRS score of 0 or 1 Exclusion Criteria: * Allergy to known study drugs or excipients * Experienced stroke in latest 3 month * Volume of Hematoma \> 5 ml in other bleeding position * Obstructive hydrocephalus * Any diagnosis as other than hypertensive ICH * Unconsciousness * Severe concurrent illness with life expectancy less than 90 days * Pregnancy or breast-feeding

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The proportionof Participants With modified Rankin Scale (mRS) 0 ~ 1

Timeframe: 90 days after the first dose of study treatment

Trial details

NCT IDNCT04714177

SponsorFirst Affiliated Hospital, Sun Yat-Sen University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-01

Contact for this trial

Xiaofei Feng, MD

+86 18601203770 xiaofeimed@163.com

View on ClinicalTrials.gov More Intracerebral Hemorrhage trials

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.